Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases
Clinical and Investigative Medicine · 19.02.2017 · 40 (1) · E34-E39
DOI: 10.25011/cim.v40i1.28052 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Clinical and Investigative Medicine, erschienen am 19.02.2017. Verfasst von Karol Majewski und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Immunology, Medical University of Lodz; Pulmonary Disease Hospital, Lodz . email@email.com. Die Arbeit wurde bisher 10-mal zitiert (Crossref).
Abstract (Originalsprache)
Purpose
The antimicrobial peptide cathelicidin LL-37 plays a role in the immune response in the course of lung infections; however, the exact role of LL-37 in defense mechanisms against bacteria within the respiratory tract is has not been precisely described. The aim of our study was to evaluate LL-37 concentrations in the serum of pulmonary tuberculosis (TB) patients, patients with pneumonia caused by Gram-positive and Gram-negative bacteria and to compare them with those of healthy subjects.
Methods
Thirty TB patients, 30 patients with pneumonia caused by Gram-positive bacteria, 30 patients with pneumonia caused by Gram-negative bacteria, and 30 healthy control subjects were enrolled in the study. Serum LL-37 concentration was measured using an enzyme-linked immunosorbent assay (ELISA).
Results
The mean (± SEM) LL-37 concentration in patients with TB (13.94±5.13 ng/mL) was significantly higher than that in patients with Gram-positive bacteria-induced pneumonia (7.87±4.58 ng/mL, P=0.00077), in patients with Gram-negative bacteria-induced pneumonia (10.27±3.60 ng/mL, P=0.00730), and in control healthy subjects (1.75±0.71 ng/mL, P=0.00004).
Conclusion
Our data suggest that cathelicidin LL-37 is an important element of host defense in the course of bacterial diseases within the respiratory tract, particularly when the infection is caused by an intracellular pathogen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Experimental Immunology, Medical University of Lodz; Pulmonary Disease Hospital, Lodz . email@email.com.
Zitieren
APA
Majewski, K., Żelechowska, P., & Brzezińska-Błaszczyk, E. (2017). Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases. Clinical and Investigative Medicine, 40(1), E34-E39. https://doi.org/10.25011/cim.v40i1.28052
Vancouver
Majewski K, Żelechowska P, Brzezińska-Błaszczyk E. Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases. Clinical and Investigative Medicine. 2017;40(1):E34-E39. doi:10.25011/cim.v40i1.28052
BibTeX
@article{Majewski2017,
author = {Majewski, Karol and Żelechowska, Paulina and Brzezińska-Błaszczyk, Ewa},
title = {Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases},
journal = {Clinical and Investigative Medicine},
year = {2017},
volume = {40},
number = {1},
pages = {E34--E39},
doi = {10.25011/cim.v40i1.28052}
}
EUVIMED